Literature DB >> 33830966

An EUA for bamlanivimab and etesevimab for COVID-19.

.   

Abstract

Entities:  

Keywords:  COVID-19; adverse effects; bamlanivimab; casirivimab; dosage; efficacy; etesevimab; imdevimab; safety

Year:  2021        PMID： 33830966

Source DB:  PubMed          Journal:  Med Lett Drugs Ther        ISSN： 0025-732X            Impact factor:   1.909


× No keyword cloud information.
  10 in total

1.  Intravenous bamlanivimab use associates with reduced hospitalization in high-risk patients with mild to moderate COVID-19.

Authors:  Ravindra Ganesh; Colin F Pawlowski; John C O'Horo; Lori L Arndt; Richard F Arndt; Sarah J Bell; Dennis M Bierle; Molly Destro Borgen; Sara N Hanson; Alexander Heyliger; Jennifer J Larsen; Patrick J Lenehan; Robert Orenstein; Arjun Puranik; Leigh L Speicher; Sidna M Tulledge-Scheitel; A J Venkatakrishnan; Caroline G Wilker; Andrew D Badley; Raymund R Razonable
Journal:  J Clin Invest       Date:  2021-10-01       Impact factor: 14.808

Review 2.  Molecular characteristics, immune evasion, and impact of SARS-CoV-2 variants.

Authors:  Cong Sun; Chu Xie; Guo-Long Bu; Lan-Yi Zhong; Mu-Sheng Zeng
Journal:  Signal Transduct Target Ther       Date:  2022-06-28

Review 3.  SARS-CoV-2 cell entry and targeted antiviral development.

Authors:  Zinuo Chen; Ruikun Du; Jazmin M Galvan Achi; Lijun Rong; Qinghua Cui
Journal:  Acta Pharm Sin B       Date:  2021-05-13       Impact factor: 11.413

4.  VarEPS: an evaluation and prewarning system of known and virtual variations of SARS-CoV-2 genomes.

Authors:  Qinglan Sun; Chang Shu; Wenyu Shi; Yingfeng Luo; Guomei Fan; Jingyi Nie; Yuhai Bi; Qihui Wang; Jianxun Qi; Jian Lu; Yuanchun Zhou; Zhihong Shen; Zhen Meng; Xinjiao Zhang; Zhengfei Yu; Shenghan Gao; Linhuan Wu; Juncai Ma; Songnian Hu
Journal:  Nucleic Acids Res       Date:  2022-01-07       Impact factor: 16.971

5.  Monoclonal Antibody Therapy for COVID-19: A Public Health Perspective From Arkansas.

Authors:  Atul Kothari; Elizabeth Woodland Borella; Michelle R Smith
Journal:  Open Forum Infect Dis       Date:  2022-01-10       Impact factor: 3.835

6.  Potent Neutralization of Omicron and other SARS-CoV-2 Variants of Concern by Biparatopic Human VH Domains.

Authors:  Chuan Chen; James W Saville; Michelle M Marti; Alexandra Schäfer; Mary Hongying Cheng; Dhiraj Mannar; Xing Zhu; Alison M Berezuk; Anupam Banerjee; Michele D Sobolewski; Andrew Kim; Benjamin R Treat; Priscila Mayrelle Da Silva Castanha; Nathan Enick; Kevin D McCormick; Xianglei Liu; Cynthia Adams; Margaret Grace Hines; Zehua Sun; Weizao Chen; Jana L Jacobs; Simon M Barratt-Boyes; John W Mellors; Ralph S Baric; Ivet Bahar; Dimiter S Dimitrov; Sriram Subramaniam; David R Martinez; Wei Li
Journal:  bioRxiv       Date:  2022-02-24

7.  Effectiveness and Safety of Regdanvimab in Patients With Mild-To-Moderate COVID-19: A Retrospective Cohort Study.

Authors:  Susin Park; Nam Kyung Je; Dong Wan Kim; Miran Park; Jeonghun Heo
Journal:  J Korean Med Sci       Date:  2022-04-04       Impact factor: 2.153

8.  Immune Escape Mechanisms of SARS-CoV-2 Delta and Omicron Variants against Two Monoclonal Antibodies That Received Emergency Use Authorization.

Authors:  Danyang Xiong; Xiaoyu Zhao; Song Luo; Yalong Cong; John Z H Zhang; Lili Duan
Journal:  J Phys Chem Lett       Date:  2022-06-27       Impact factor: 6.888

9.  SARS-CoV-2 neutralizing antibodies for COVID-19: Outcomes for bamlanivimab versus bamlanivimab-etesevimab combination in a racially diverse cohort of patients with significant comorbidities.

Authors:  Lea M Monday; Indira Brar; George Alangaden; Mayur S Ramesh
Journal:  J Clin Pharm Ther       Date:  2022-05-28       Impact factor: 2.145

10.  Safety and Tolerability of Monoclonal Antibody Therapies for Treatment of COVID-19 in Pediatric Patients.

Authors:  Gregory Mak; Aimee M Dassner; Benjamin M Hammer; Benjamin R Hanisch
Journal:  Pediatr Infect Dis J       Date:  2021-12-01       Impact factor: 3.806
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.